CARsgen Therapeutics Holdings Limited, a company focused on developing innovative CAR T-cell therapies, has signed Strategic Cooperation Agreements with Shanghai Jingong Enterprise, which is a key platform enterprise in the Bay Area High-Tech Zone of Jinshan District, Shanghai.

With a total investment amount not exceeding $53.6 million, the Company will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai.

This move closely aligns with the commercialization progress of the Company’s multiple CAR T-cell products, including the marketed product zevorcabtagene autoleucel and the CAR T-cell product satricabtagene autoleucel for solid tumor currently in the NDA stage. It also lays the foundation for the future mass production of multiple allogeneic CAR T-cell products (such as CT0596 and CT1190B).

This transaction requires no significant capital expenditure from CARsgen Therapeutics in early stage, thus effectively preserving valuable cash flow for core research and development as well as market expansion. In addition, the repurchase mechanism ensures the Company can fully acquire asset control after long-term operation, maintaining production stability and enhancing the flexibility of asset layout.

This strategic partnership aims to further consolidate CARsgen Therapeutics’ leading position in the global CAR T-cell therapy industry while creating long-term value for shareholders.

Related News

Last year, BioDuro, a global contract research, development, and manufacturing organization, opened a new laboratory in the Waigaoqiao district/Free-Trade Zone of Shanghai, China.